A multinational research team led by Professor Małgorzata Kujawska at the Poznań University of Medical Sciences in Poland has discovered that graphene quantum dots (GQDs)—nanoscale carbon particles—can counteract the clumping of α-synuclein (ASN) protein, a hallmark of neurodegenerative diseases such as Parkinson's disease and multiple system atrophy (MSA). The findings, published in the journal Science and Technology of Advanced Materials (STAM), represent a promising step toward developing nanomaterial-based therapies for these conditions.
Accumulation of ASN into toxic aggregates is associated with cellular dysfunction and progressive neuronal loss in synucleinopathies. Current treatments only manage symptoms rather than addressing the underlying protein clumping. The study employed a multi-stage approach, testing GQDs in cell-free environments, neuronal cultures, and animal models of MSA. When administered intranasally in mice, GQDs significantly reduced the presence of toxic protein aggregates. Additionally, the treatment appeared to activate autophagy, a cellular recycling process that helps break down damaged proteins.
At concentrations relevant to its biological effects, GQDs showed a favorable safety profile, although some changes in cellular stress and immune responses were observed at higher doses. This is an important consideration, as biocompatibility remains a hurdle for many nanomaterials in medical applications. Challenges such as preventing quantum dots from clumping in liquid suspensions also persist.
“This study points to a promising new direction for strategies against neurodegenerative diseases,” says Professor Kujawska. “While clinical use of GQDs remains a long way off, these findings strengthen the case for further research.” She added, “GQDs may serve as a useful research tool. What we learn as we optimize their properties and conduct a comprehensive safety evaluation could help design more effective nanomaterial-based strategies not just for synucleinopathies, but also for other conditions characterized by the buildup of toxic proteins.”
The research, published in the open-access journal STAM, which is available at https://www.tandfonline.com/STAM, underscores the potential of engineered carbon-based nanomaterials in interfering with misfolded protein aggregation. While further studies are needed to translate these findings into clinical applications, the work provides a foundation for future exploration of GQDs as therapeutic agents in neurodegenerative diseases.
